Stryker's Suppliers recorded an increase in sales by 1.31 % year on year in Q2 2026, sequentially sales grew by 2.61 %, Stryker's cost of sales deteriorated by -4.13 % year on year, relative to one quarter ago cost of sales fell by -5.38 % in Q2.
Stryker's Suppliers recorded an increase in sales by 1.31 % year on year in Q2 2026, sequentially sales grew by 2.61 %, Stryker's cost of sales deteriorated by -4.13 % year on year, compare to one quarter ago cost of sales fell by -5.38 % in Q2.
Raw materials essential to the business are generally available from multiple sources; however, certain raw materials are currently sourced from single suppliers. Most manufactured products are stocked in inventory, while some MedSurg products are assembled to order.
Stryker's Comment on Supply Chain
Raw materials essential to the business are generally available from multiple sources; however, certain raw materials are currently sourced from single suppliers. Most manufactured products are stocked in inventory, while some MedSurg products are assembled to order.
SYK's Suppliers Net profit fell by
SYK's Suppliers Net margin fell in Q2 to
-3.94 %
7.1 %
SYK's Suppliers Net profit fell by -3.94 %
SYK's Suppliers Net margin fell in Q2 to 7.1 %
Stryker's Suppliers Sales Growth
in Q2 2026 by Industry
Sources:
Stryker Corp's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Stryker Corp’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
1.31 %